Technologyreview Science Corporation's PRIMA Implant Shows Promise for Vision Restoration
Article Content
- •PRIMA implant successfully tested in Stargardt disease patient.
- •Device combines retinal implant with camera-equipped glasses.
- •Awaiting FDA clearance after European approval in July 2026.
Science Corporation has successfully implanted its PRIMA vision-restoring chip in a patient with Stargardt disease, a condition leading to central vision loss. The implant, which mimics photoreceptors, is designed to transmit visual information to healthy retinal cells. During rehabilitation, the patient was able to see letters and read words for the first time since losing vision. The PRIMA system combines a retinal implant with camera-equipped glasses, providing a new treatment option for patients with advanced age-related macular degeneration (AMD) and Stargardt disease. The device is currently awaiting FDA clearance in the US after being approved in Europe in July 2026. Approximately 150,000 people worldwide suffer from Stargardt disease, with no current cure available. The device's development marks a significant advancement in brain-computer interface technology, aiming to restore vision by leveraging the body's natural processing capabilities.
Ask AI about this cluster
Answers cite the sources they use